Whanin Pharm (016580) — Cash Flow Quality Index
Whanin Pharm (016580) has a Cash Flow Quality Index of 1.18x as of December 2025. Operating cash flow of ₩2.38 Billion exceeds net income of ₩2.01 Billion, indicating high earnings quality where cash backs reported profits. Explore how much of Whanin Pharm's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Whanin Pharm Cash Flow Quality Index (2009–2025)
Historical Cash Flow Quality Index for Whanin Pharm across 14 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check tangible net worth ratio of Whanin Pharm to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for Whanin Pharm (2009–2025)
Year-by-year earnings quality comparison for Whanin Pharm. For live market cap and the full company financial profile, see Whanin Pharm (016580) market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.67x | ₩9.04 Billion | ₩13.60 Billion | ▼ -22.7% |
| 2024 | 0.86x | ₩20.69 Billion | ₩24.06 Billion | ▲ +10.4% |
| 2023 | 0.78x | ₩23.20 Billion | ₩29.77 Billion | ▲ +10.6% |
| 2022 | 0.70x | ₩16.85 Billion | ₩23.92 Billion | ▼ -46.8% |
| 2021 | 1.32x | ₩35.32 Billion | ₩26.66 Billion | ▲ +36.2% |
| 2020 | 0.97x | ₩22.75 Billion | ₩23.39 Billion | ▼ -26.4% |
| 2019 | 1.32x | ₩24.73 Billion | ₩18.70 Billion | ▲ +63.1% |
| 2018 | 0.81x | ₩17.45 Billion | ₩21.52 Billion | ▼ -6.1% |
| 2017 | 0.86x | ₩23.48 Billion | ₩27.17 Billion | ▼ -28.5% |
| 2016 | 1.21x | ₩19.82 Billion | ₩16.40 Billion | ▼ -9.5% |
| 2012 | 1.34x | ₩21.11 Billion | ₩15.80 Billion | ▲ +29.2% |
| 2011 | 1.03x | ₩15.12 Billion | ₩14.61 Billion | ▲ +18.0% |
| 2010 | 0.88x | ₩15.12 Billion | ₩17.24 Billion | ▼ -32.0% |
| 2009 | 1.29x | ₩18.61 Billion | ₩14.43 Billion | — |